Stockscreener 앱 받기
1.16
16.00%
0.16
시간 외 거래:
1.18
0.02
+1.72%
Clearmind Medicine Inc 주식(CMND)의 최신 뉴스
Is Clearmind Medicine Inc. a good long term investmentExplosive earnings growth - jammulinksnews.com
How Clearmind Medicine Inc. stock reacts to Fed policy changesFree Access to Community with 300% Return - beatles.ru
What drives Clearmind Medicine Inc. stock priceExceptional gains - Autocar Professional
What analysts say about Clearmind Medicine Inc. stockUnstoppable profit momentum - jammulinksnews.com
Clearmind Medicine Inc. Stock Analysis and ForecastPhenomenal trading returns - jammulinksnews.com
What makes Clearmind Medicine Inc. stock price move sharplySmart Money Trade Setups - beatles.ru
Clearmind Expands its Clinical Trial for Alcohol Use, New Site Activated and Additional Participant Enrolled - MarketScreener
How Clearmind Medicine Inc. stock performs during market volatilityFree High-Accuracy Stock Picks - Newser
Why Clearmind Medicine Inc. stock attracts strong analyst attentionTriple Return With Stability - Newser
Clearmind Expands Its Clinical Trial for Alcohol Use: New Site Activated and Additional Participant Enrolled - MarketScreener
Clearmind expands phase I/IIa trial for alcohol use disorder treatment By Investing.com - Investing.com South Africa
Clearmind expands phase I/IIa trial for alcohol use disorder treatment - Investing.com India
Clearmind Medicine Inc. Expands Phase I/IIa Clinical Trial for CMND-100 to Johns Hopkins University to Address Alcohol Use Disorder - Nasdaq
Clearmind Expands its Clinical Trial for Alcohol Use: New Site Activated and Additional Participant Enrolled - The Manila Times
Clearmind Medicine (NASDAQ:CMND) Stock Price Up 4.5% – Here’s Why - Defense World
Alcohol Use Disorder Market Report 2025-2035 Featuring Clearmind Medicine, Purdue Pharma, Psyence Biomedical, Eli Lilly and Co, Tempero Bio,, Nxera Pharma, Novo Nordisk, Adial, Alkermes, Lundbeck - Yahoo Finance
Clearmind Medicine Soars 32.89% on Clinical Trial Approval - AInvest
CMND’s Stock Market Odyssey: A Year of Growth, Decline, and Resilience - investchronicle.com
Clearmind Gains IRB Approval At TASMC For Alcohol Use Disorder Drug Trial - Nasdaq
Clearmind’s Stock Gains Momentum with New Trial Expansions - timothysykes.com
Clearmind Medicine’s Rise: What’s Steering the Surge? - timothysykes.com
Clearmind receives IRB approval for alcohol disorder treatment trial - Investing.com
Clearmind receives IRB approval for alcohol disorder treatment trial By Investing.com - Investing.com South Africa
Clearmind Medicine Inc. Receives IRB Approval for Phase 1/2a Clinical Trial of CMND-100 for Alcohol Use Disorder - Nasdaq
Clearmind Medicine Announces First Participant Ever Dosed with its CMND-100 Treatment in Groundbreaking Clinical Trial for Alcohol Use Disorder - The Manila Times
Clearmind doses first participant in alcohol disorder treatment trial - Investing.com
Clearmind doses first participant in alcohol disorder treatment trial By Investing.com - Investing.com Canada
Clearmind Medicine's Global AUD Trial Expansion: Seizing the $775M Market's Psychedelic Opportunity - AInvest
Clearmind adds Hadassah Medical Center to alcohol disorder drug trial By Investing.com - Investing.com South Africa
Clearmind Adds New Site to Trial for Experimental Alcohol Use Disorder Drug - MarketScreener
Clearmind enrolls first patient in CMND-100 alcohol disorder trial - Investing.com India
Clearmind Medicine Enrolls First Patient in its Clinical Trial for Alcoholism Treatment - Yahoo Finance
Clearmind Medicine Inc. Engages Consulting Firm to Advance Psychedelic-Based Treatments and Regulatory Advocacy - Nasdaq
Clearmind adds Tel Aviv medical center to alcohol disorder drug trial - Investing.com India
Clearmind Medicine Inc. Expands Phase I/IIa Clinical Trial for CMND-100 with Tel Aviv Sourasky Medical Center Collaboration - Nasdaq
Weekly Roundup on the Cannabis Sector & Psychedelic Sector - marketexclusive.com
Clearmind Medicine Inc. (NASDAQ:CMND) Short Interest Update - Defense World
Clearmind Medicine Retains Crescendo Communications LLC. for Investor Relations and Announces Granting of Stock and Warrants - Psychedelic Alpha
Clearmind Medicine Inc. (NASDAQ:CMND) Shares Acquired by Citadel Advisors LLC - Defense World
# Clearmind Medicine hires lobbying firm to advance psychedelic therapy By Investing.com - Investing.com South Africa
# Clearmind Medicine hires lobbying firm to advance psychedelic therapy - Investing.com Australia
Clearmind Medicine Engages Leading Government and Political Affairs Firm to Advance Psychedelic Therapeutics - The Manila Times
Clearmind Medicine Partners with Leading Government Affairs Firm to Advance Psychedelic Therapeutics - Nasdaq
Clearmind Medicine Engages Leading Government and Political Affairs Firm to Advance Psychedelic ... - Bluefield Daily Telegraph
0.87%
0.17%
자본화:
|
볼륨(24시간):